ProCE Banner Activity

Rationale for Targeted Therapy Toward BTK in B-Cell Malignancies

Slideset Download
In this downloadable slideset, John C. Byrd, MD, provides the rationale for targeting BTK with inhibitors in patients with B-cell malignancies.

Released: June 05, 2019

Expiration: June 03, 2020

No longer available for credit.

Share

Faculty

John C. Byrd

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio